ProQR Therapeutics (PRQR) Total Current Liabilities (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Total Current Liabilities for 14 consecutive years, with $39.9 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 3.98% year-over-year to $39.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.9 million (up 3.98% YoY) and the FY2025 annual result came in at $36.9 million, down 16.61% from the prior year.
• Total Current Liabilities rose to $39.9 million in Q1 2026 per PRQR's latest filing, from $36.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for PRQR reached as high as $45.1 million in Q3 2024 and fell as low as $19.5 million in Q1 2023.
• A 5-year average of $34.6 million and a median of $37.7 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 225886.28% — and 2023, when it fell 27.64%.
• Year by year, Total Current Liabilities stood at $23.9 million in 2022, then surged by 62.96% to $38.9 million in 2023, then rose by 13.74% to $44.3 million in 2024, then decreased by 16.61% to $36.9 million in 2025, then advanced by 8.07% to $39.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $39.9 million, $36.9 million, and $37.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.